1. Measured by its binding ability in a functional ELISA. Immobilized human IL1RA at 10 μg/ml (100 μl/well) can bind human IL1R2-Fc , The EC50 of human IL1R2-Fc is 0.04-0.1 μg/mL. 2. Measured by its binding ability in a functional ELISA. Immobilized human IL1RA at 10 μg/ml (100 μl/well) can bind human IL1R1-Fc , The EC50 of human IL1R1-Fc is 0.08-0.2 μg/mL. 3. Measured by its ability to induce Interferon gamma secretion by human natural killer lymphoma NK-92 cells in the presence of 250pg/mL IL1a. The EC50 for this effect is typically 3-12 ng/mL.

IL-1RA Protein, Human, Recombinant is expressed in E. coli expression system. The predicted molecular weight is 17.3 kDa and the accession number is P18510-1.

Human

E. coli

MVCD4,IRAP,interleukin 1 receptor antagonist,IL-1RN,IL-1ra3,IL-1ra,IL1RA,IL1F3,ICIL-1RA,DIRA

A DNA sequence encoding the mature form of human IL1RA isoform1 (NP_776214.1) (Arg 26-Glu 177) was expressed. Predicted N terminal: Met

≥ 95 % as determined by SDS-PAGE

A Certificate of Analysis (CoA) containing reconstitution instructions is included with the products. Please refer to the CoA for detailed information.

It is recommended to store recombinant proteins at -20°C to -80°C for future use. Lyophilized powders can be stably stored for over 12 months, while liquid products can be stored for 6-12 months at -80°C. For reconstituted protein solutions, the solution can be stored at -20°C to -80°C for at least 3 months. Please avoid multiple freeze-thaw cycles and store products in aliquots.

Interleukin-1 receptor antagonist (IL-1RA) also known as IL1RN is a member of the interleukin 1 cytokine family. This protein inhibits the activities of interleukin 1, alpha (IL1A), and interleukin 1, beta (IL1B), and modulates a variety of interleukin 1 related immune and inflammatory responses. A polymorphism of this protein-encoding gene is reported to be associated with an increased risk of osteoporotic fractures and gastric cancer. IL-1RA/IL1RN may inhibit the activity of IL-1 by binding to its receptor and it has no IL-1 like activity. Genetic variation in IL-1RA/IL1RN is associated with susceptibility to microvascular complications of diabetes type 4 (MVCD4). These are pathological conditions that develop in numerous tissues and organs as a consequence of diabetes mellitus. They include diabetic retinopathy, diabetic nephropathy leading to end-stage renal disease, and diabetic neuropathy. Diabetic retinopathy remains the major cause of new-onset blindness among diabetic adults. It is characterized by vascular permeability and increased tissue ischemia and angiogenesis. Defects in IL-1RA/IL1RN are the cause of interleukin 1 receptor antagonist deficiency (DIRA) which is also known as deficiency of interleukin 1 receptor antagonist. Autoinflammatory diseases manifest inflammation without evidence of infection, high-titer autoantibodies, or autoreactive T-cells. DIRA is a rare, autosomal recessive, genetic autoinflammatory disease that results in sterile multifocal osteomyelitis, and pustulosis from birth.